Putnam Investments LLC Chinook Therapeutics, Inc. Transaction History

Putnam Investments LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 22, 2023	SELL	$21.53 - $26.8 $64,590 - $80,400	-3,000 Reduced 1.64%	180,343 $4.17 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $134,136 - $196,920	-7,200 Reduced 3.78%	183,343 $4.8 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $3.34 Million - $4.45 Million	190,543 New	190,543 $3.75 Million
Q2 2022 Aug 15, 2022	SELL	$12.59 - $18.8 $423,955 - $633,071	-33,674 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $18,751 - $26,036	1,560 Added 4.86%	33,674 $551,000
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $343,298 - $540,478	32,114 New	32,114 $523,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Putnam Investments LLC with notifications on news.